Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Vertex, CFFT collaborate on cystic fibrosis correctors
May 2011
SHARING OPTIONS:

CAMBRIDGE, Mass.Vertex Pharmaceuticals Inc. and Cystic Fibrosis Foundation Therapeutics Inc. (CFFT) have announced a new collaboration to continue the discovery and development of correctors to treat the underlying cause of cystic fibrosis in people suffering from the most common form of the disease. The collaboration will support the development of VX-661 and the discovery and development of other next-gen correctors. By the end of 2011, Vertex plans to initiate a Phase II study of VX-661 in cystic fibrosis patients with the F508del mutation. Per the collaboration, CFFT will fund Vertex with up to $75 million for research and development, and CFFT is entitled to receive royalties on future net sales of any correctors developed as a result of the collaboration.


Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.